Condition

Triple Negative Breast Cancer Metastatic

ClinicalTrials.gov condition label

Clinical trials3

Recruiting2

Common interventions8

Lead sponsors shown3

Clinical trials

3 shown

A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.NCT06889610 · 2026-03-30

RECRUITING

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-PaclitaxelNCT05582538 · 2022-12-15

RECRUITING

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)NCT07413601 · 2026-02-10

NOT_YET_RECRUITING

Common interventions

CeralasertibDRUG1Cisplatin/ CarboplatinDRUG1DurvalumabDRUG1MTT(Multimodal Tumor Thermal Therapy System)- Colorectal CancerCOMBINATION_PRODUCT1MTT(Multimodal Tumor Thermal Therapy System)- MelanomaCOMBINATION_PRODUCT1MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast CancerCOMBINATION_PRODUCT1Nab-paclitaxelDRUG1QL1706DRUG1

Leading sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences1Fudan University1IFOM ETS - The AIRC Institute of Molecular Oncology1

Trial status mix

RECRUITING2

NOT_YET_RECRUITING1

Phase mix

PHASE23

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.